GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (MEX:GRF N) » Definitions » Institutional Ownership

Grifols (MEX:GRF N) Institutional Ownership : 11.69% (As of Jul. 08, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Grifols Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Grifols's institutional ownership is 11.69%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Grifols's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Grifols's Float Percentage Of Total Shares Outstanding is 61.89%.


Grifols Institutional Ownership Historical Data

The historical data trend for Grifols's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Institutional Ownership Chart

Grifols Historical Data

The historical data trend for Grifols can be seen below:

2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30 2025-05-31 2025-06-30
Institutional Ownership 17.06 16.79 16.51 15.98 15.51 15.76 11.24 11.29 11.32 11.69

Grifols Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Grifols Business Description

Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Grifols Headlines

No Headlines